March 1, 2019 - The case was voluntarily dismissed.

October 4, 2018 - An investor in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by TG Therapeutics, Inc. in connection with certain allegedly false and misleading statements made between June 4, 2018 and September 25, 2018.

New York based TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States.

On September 25, 2018, TG Therapeutics issued a press release announcing “that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review ongoing data from the study and advised the Company that the interim analysis of Overall Response Rate (ORR) could not be conducted at this time as the data were not sufficiently mature to conduct the analysis.”

Shares of TG Therapeutics, Inc. declined from almost $13 per share in early September 2018 to as low as $4.95 per share on September 26, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of TG Therapeutics, Inc. (NASDAQ: TGTX) common shares between June 4, 2018 and September 25, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 4, 2018 and September 25, 2018, the defendants failed to disclose that TG was involved in cleaning the data collected in the UNITY-CLL Trial and, as a result, was able to gain an understanding as to the efficacy of the combination therapy; that, as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal, and that, as a result, the Company would not be able to seek accelerated approval; and that, given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival – in other words, the drug therapy had failed. As a result of defendants’ false statements and/or omissions, the price of TG common stock was artificially inflated during the Class Period to as high as $14.70 per share.